Drug Profile


Alternative Names: FATE-NK100

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Fate Therapeutics
  • Class Cell therapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Mar 2017 Fate Therapeutics and Masonic Cancer Center plan a clinical trial for Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (NCT03081780)
  • 13 Mar 2017 US FDA approves IND application for FATE NK100 in Acute myeloid leukaemia (Late-stage disease)
  • 07 Nov 2016 Fate Therapeutics files an IND application with the FDA in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top